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A b s t r a c t
Background: General anaesthesia may have negative impact on patient mortality and morbidity, as well as overall procedure 
costs, in atrial septal occluder (ASO) implantation.
Aim: We sought to evaluate the safety, efficacy, and feasibility of conscious sedation for transcatheter implantation of ASOs.
Methods: A total of 122 patients referred for transcatheter implantation of ASO were included. Mean patient age was 
51 ± 15 years, and 43 (35%) patients were male. The initial dose of midazolam was 2 mg and fentanyl dose was 25 µg. Ad-
ditional doses of midazolam and fentanyl were administered, if necessary. Patient responsiveness was assessed every 10 min, 
and the sedatives doses were titrated in order not to exceed grade 3 sedation in the Ramsey scale.
Results: Atrial septal occluders were successfully implanted in the majority of patients (98.4%). In two (1.6%) cases the proce-
dure failed because of too small patent foramen ovale (PFO) diameter (n = 1, 0.8%) or device instability (n = 1, 0.8%). The 
mean duration of procedure was 47.6 ± 28.4 min and was similar for ASD and PFO closure (p = 0.522). The overall mean 
dose of midazolam was 4.7 ± 2.2 mg (63.9 ± 32.5 µg/kg) and fentanyl was 30.0 ± 11.9 µg (0.43 ± 0.17 µg/kg). Median 
entrance dose of radiation at the patient plane was 25 (interquartile range: 16–57) mGy, and did not differ between ASD and 
PFO procedures (p = 0.614). The majority of patients were free of complications (91.0%). The following early complications 
were observed: transient ischaemic attack (n = 2, 1.6%), supraventricular arrhythmias (n = 4, 3.3%), left atrial thrombus 
formation (n = 1, 0.8%), symptomatic bradycardia (n = 1, 0.8%), and femoral venous bleeding (n = 5, 4.1%). After mean 
follow-up of 386 days residual shunt was observed in eight (6.6%) patients.
Conclusions: Conscious sedation for transcatheter implantation of ASO is a feasible, safe, and efficient technique, allowing 
successful PFO and ASD closure in the majority of patients.
Key words: atrial septal defect, patent foramen ovale, septal occluder device, feasibility studies, conscious sedation,  
transcatheter closure
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INTRODUCTION
Rapid technological and medical advancements have made 
interventional procedures like percutaneous atrial septal 
defect occluders (ASO), patent ductus arteriosus, and ven-
tricular septal defect occluder implantation widely available 
and used. Since the first nonsurgical closure of an atrial septal 
defect (ASD) in 1976 [1], multiple devices and procedural 
approaches have emerged. Optimal sedation and anaes-
thesia strategies during these procedures are still actively 
being investigated. General anaesthesia or deep sedation is 
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required for most transcatheter ASO implantation procedures 
to prevent patient pain and discomfort. However, it may 
have a negative impact on patient mortality and morbidity, 
as well as overall procedure costs. There is still no consensus 
regarding recommendations for anaesthetic management in 
interventional cardiology, and anaesthetic approaches during 
transcatheter ASO implantations procedures vary between 
different centres.
This study was designed to evaluate the safety, efficacy, 
and clinical feasibility of conscious sedation for transcath-
eter closure of atrial ASDs in adults, using two-dimension-
al/three-dimensional (2D/3D) transoesophageal echocardio-
graphy (TEE) guidance and presenting a single-centre ex-
perience.
METHODS
Our study was a retrospective, single-centre, observation-
al study.
Study population
Patients with TEE confirmed ASD or patent foramen ovale 
(PFO) and prior episode of cryptogenic stroke/transient ischae-
mic attack (TIA) due to a presumed paradoxical embolism, 
as determined by a cardiologist and neurologist following 
an evaluation to exclude known causes of ischaemic stroke 
or right ventricle volume overload related to predominant 
left-to-right interatrial shunt, were eligible.
The following exclusion criteria were applied:
 — anatomy other than ASD ostium secundum type or PFO 
or the presence of other congenital cardiac deformities 
requiring surgery;
 — intracardiac mass, vegetation, tumour, or thrombus at the 
intended site of implantation;
 — tissue rim other than aortic smaller than 5 mm in the 
case of ASD;
 — active endocarditis or other untreated infection;
 — documented severe, irreversible pulmonary arterial hy-
pertension;
 — contraindications for aspirin or clopidogrel;
 — age < 18 years or > 65 years.
Procedure details on 2D/3D TEE-guided  
occluder implantation
The whole implantation procedure was monitored using 
2D/3D-TEE guidance with the E9 Vivid (GE Vingmed, 
Norway) and iE33 (Philips Health Systems). Device sizing 
was done using 2D and 3D measurements, according to 
the manufacturer’s instructions and echocardiographic 
guidelines [2, 3]. No additional balloon device sizing 
was performed.
The loading dose of 300 mg of clopidogrel was admin-
istered prior to procedure. Initial bolus of 5000 IU of unfrac-
tionated heparin (UFH), followed by adequate UFH dosing 
intravenously, was administered to keep the activated clotting 
time  greater than 200 s throughout the procedure.
The right femoral vein access was used to perform stand-
ard right heart catheterisation. 
Implantations protocols differed in their details between 
the occluders producers. In general, the guidewire was intro-
duced into the left atrium via ASD/PFO under TEE guidance. 
The delivery sheath was then advanced over the guidewire 
through the communications into the left upper pulmonary 
vein. The correct position of the delivery sheath was verified 
by TEE. Then, the guidewire was removed and the device was 
advanced into the delivery sheath by pushing the delivery 
cable. Under TEE and fluoroscopic guidance, the left atrial 
disc was deployed with its proper position controlled by the 
device gently pulling against the atrial septum, which could 
be felt and also observed in TEE as atrial septum tenting. 
Subsequently, the right atrial disc was delivered. A secure 
position of the occluder across the ASD or PFO was assured 
using gentle motions with the delivery cable along with TEE 
control. The delivery cable was released from the device only 
if there was no device interference with any adjacent cardiac 
structure (such as superior vena cava, pulmonary vain, mitral 
valve, coronary sinus, aorta).
Figure 1A and B present the intra-ASD before and after 
occluder implantation with the use of 3D TEE.
During the procedure and up to 6 h after procedure, 
haemodynamic and respiratory parameters (blood pressure 
[BP], heart rate, electrocardiogram [ECG], SpO2 with the use 
of continuous pulse oximetry, and respiratory rate with the 
use of transthoracic impedance continuous measurement with 
electrocardiography) were monitored.
Primary sedation safety outcomes were defined as 
adverse sedative effects such as: respiratory depression 
(SpO2 < 90% for at least 20 s) or persistent hypotension 
(systolic BP < 90 mmHg). In safety analysis the need for en-
dotracheal intubation or consultation of an anaesthesiologist 
because of spontaneous ventilation problems or cardiovas-
cular instability were evaluated.  
Total procedure time, entrance dose of radiation at the 
patient plane (EFD), and overall dose of analgesics and seda-
tives were calculated for each procedure. 
Procedure details on conscious sedation
All patients received conscious sedation. The loading dose of 
midazolam was 2 mg and loading fentanyl dose was 25 µg 
intravenously in slow infusion over several minutes. Additional 
doses of midazolam and fentanyl were administered during 
procedure course, if necessary. Midazolam and fentanyl were 
administered gradually to maintain amnesia and analgesia. 
The patient’s responsiveness in Ramsay Sedation Score was 
assessed every 10 min with sedation kept at the Ramsey Se-
dation Scale not deeper than grade 3 in the Ramsey score. 
The administration of analgesic and sedative medication 
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were performed under the instruction and supervision of the 
cardiologist performing the occluder implantation procedure.
Figure 2 presents the conscious sedation protocol.
Post-procedural care
All patients were transferred to the intensive cardiac care unit 
and monitored after the procedure for up to 6 h — BP (every 
5 min), heart rate, ECG, respiratory rate, SpO2 (continuously) 
with appropriate sound alarms. If no adverse respiratory 
(desaturation, apnoea) and haemodynamic (hypotension) 
events occurred, they were transferred to the general ward. 
The patient remained supine for up to 2 h until the venous 
sheath was removed. 
Aspirin (75 mg daily) and clopidogrel (75 mg daily) are 
were prescribed for six months (or longer and in different 
dose according to device characteristics).
The patients were discharged from the hospital the day 
after the procedure, in the case of no local vascular complica-
tions and if appropriate device position was confirmed one 
day post-implant transthoracic echocardiography (TTE).
The appropriate endocarditis prophylaxis for six 
months following device implantation was recommended. 
All patients were instructed to avoid strenuous activity for 
a minimum of one month post-device implant to avoid 
device erosion.
Echocardiographic follow-up
After the procedure patients were followed-up for 
12 months. TTE was performed before hospital discharge, 
as well as at three, six, and 12 months after the occluder 
implantation procedure. Follow-up TEE was performed three 
to six months after the procedure. Clinical follow-up with 
a cardiologist annually thereafter was also recommended.
Efficacy of PFO/ASD closure was defined as the absence 




(to maintain Ramsay Sedation Scale 3)
Ramsay Sedation Scale evaluation (every 10 min)START








Figure 2. Procedural conscious sedation protocol
Figure 1. Three-dimensional transoesophageal echocardiography before (A) and after (B) atrial septal defect closure
A B
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Statistical analysis
Data is presented as percentages for categorical variables 
and as mean with standard deviation (SD) or median with 
interquartile range (IQR) for continuous variables depend-
ing on their distribution. The normality of distribution was 
analysed using the Shapiro-Wilk’s test. Intergroup analysis 
was performed using the Student t-test for independent vari-
ables or the Mann-Whitney U-test depending on the variable 
distribution. The c2 test or Fisher exact probability test were 
applied for the categorical variable analysis. P-values less than 
0.05 were considered statistically significant. The overall statis-
tical analysis was performed using MedCalc version 12.0 and 
STATISTICA version 10.0.
RESULTS
A total of 122 consecutive patients with either a significant 
ostium secundum ASD (n = 67, 54.9%) or PFO (n = 55, 
45.1%) were referred for transcatheter implantation of atrial 
septal occluders between 7/05/2009 and 20/11/2015. Mean 
patients’ age was 50.6 ± 15.0 years, and 43 (35.2%) pa-
tients were male. The main indications were: secondary 
stroke and/or TIA prevention (n = 90, 73.8%) and significant 
shunting (n = 32; 26.2%). The detailed  characteristics of the 
studied group is presented in Table 1.
Devices
The following devices were implanted in ASD group: Oc-
clutech (Occlutech International AB, Helsingborg, Sweden) 
Figulla FlexTM ASD Occluder (n = 7); Cardia UltraseptTM ASD 
(n = 1); Cardia AtriaseptTM II-ASD (n = 16); MemoPartTM 
(PFM Medical) ASD Occluder (n = 16); Nit-OccludTM (PFM 
Medical) ASD-R (n = 2); AMPLATZERTM (St. Jude Medical) 
Septal Occluder (n = 27). Patients with PFO received the 
following devices: OcclutechTM (Occlutech International AB, 
Helsingborg, Sweden) Figulla FlexTM PFO Occluder (n = 2); 
Cardia AtriaseptTM II-PFO (n = 19); Cardia UltraseptTM PFO 
(n = 9); MemoPartTM (Lupu Medical) PFO Occluder (n = 10); 
Nit-OccludTM (PFM Medical) PFO (n = 12); AMPLATZERTM 
(St. Jude Medical) PFO Occluder (n = 1).
Procedure efficacy
Atrial septal occluders were successfully implanted in the 
majority of patients (n = 120, 98.4%). In two (1.6%) cases 
the procedure failed because of too small PFO diameter (in-
ability of catheter to passage through the interatrial septum) in 
one (0.8%) case and device instability in one (0.8%) patient. 
The diameter of implanted devices ranged between 9 and 
35 mm (mean occluder diameter 22.5 ± 5.8 mm). The mean 
duration of procedure was 47.6 ± 28.4 min, and was similar 
for ASD and PFO closure (48.1 ± 22.3 vs. 47.0 ± 34.4 min, 
p = 0.522; Fig. 3A). Median entrance dose of radiation at 
the patient plane (EFD) was 25 (IQR 16–57) mGy and did 
not differ between ASD and PFO procedures (p = 0.614).
Conscious sedation
The overall mean midazolam used dose was 4.7 ± 2.2 mg 
(63.9 ± 32.5 µg/kg) and the overall mean fentanyl dose was 
30.0 ± 11.9 µg (0.43 ± 0.17 µg/kg). There were no sig-
nificant differences in used doses of midazolam (p = 0.797) 
and fentanyl (p = 0.247) between PFO and ASD groups, 
retrospectively (Fig. 3B, C).
None of the studied patients needed endotracheal 
intubation or consultation of an anaesthesiologist due to 
haemodynamic instability or ventilation problems. There were 
no adverse sedative effect such as a desaturation, apnoea 
episodes, or hypotension.
Table 1. Clinical characteristics of the study group
Demographic characteristics
Male 43 (35.2%)
Age [years] 50.6 ± 15.0
Body weight [kg] 73.3 ± 16.0
Height [cm] 168.2 ± 9.4
BMI [kg/m2] 25.8 ± 4.3
SBP [mmHg] 121.6 ± 10.2
DBP [mmHg] 74.4 ± 7.5
Comorbidities
Diabetes mellitus 15 (12.3%)
Hypercholesterolaemia 48 (39.0%)
Arterial hypertension 55 (45.1%)
Heart failure 20 (16.4%)
Coronary artery disease 9 (7.3%)
Indications for ASD/PFO closure
Right heart volume overload 32 (26.2%)
Secondary stroke/TIA prevention 90 (73.8%)
Occluder implantation procedure
Occluder implantation successfully completed 120 (98.4%)
Total procedure duration [min] 47.6 ± 28.4
Entrance dose of radiation  
at the patient plane [mGy]
25 (16–57)
The diameter of implanted device [mm] 22.5 ± 5.8
Drugs
Midazolam total dose [mg] 4.7 ± 2.2
Midazolam total indexed dose [μg/kg] 63.9 ± 32.5
Fentanyl total dose [μg] 30.0 ± 11.9
Fentanyl total indexed dose [μg/kg] 0.43 ± 0.17
The data are presented as mean ± standard deviation, median with 
interquartile range or number (percentage); ASD — atrial septal  
defect; BMI — body mass index; SBP — systolic blood pressure;  
DBP — diastolic blood pressure; PFO — patent foramen ovale;  
TIA — transient ischaemic attack
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No procedure was terminated prematurely due to ad-
verse effect of sedation.
Periprocedural complications
The majority of patients were free of any complications 
(n = 111, 91.0%).
The following early complications were observed: TIA 
(n = 2, 1.6%) with symptoms resolving within 24 h, supraven-
tricular arrhythmias (n = 4, 3.3%), left atrial thrombus formation 
(n = 1, 0.8%), symptomatic bradycardia (n = 1, 0.8%), and 
femoral venous bleeding with haematoma formation without 
communication with femoral artery (n = 5, 4.1%). None of 
these access-site complications required specific treatment.
There were no device-related deaths.
Long-term results
TTE and/or TEE for diagnosing residual shunting was ob-
tained in all 120 (100%) patients with successfully implanted 
ASD/PFO occluder. After a mean follow-up of 386 days, 
residual shunt (at rest or post-Valsalva) was observed in eight 
(6.6%) patients. The presence of residual shunt was more 
common in the ASD group than in the PFO group, but the 
difference did not reach statistical significance 2/55: 3.6% 
vs. 6/67: 9.0%, p = 0.292.
There were no cases of suspected or proven device ero-
sion during the follow-up.
DISCUSSION
In this study we have demonstrated that percutaneous ASO 
implantation with 2D/3D TEE guidance, but without the use 
of general anaesthesia, is feasible and highly successful. The 
described procedure in a high-volume TEE and percutaneous 
procedure centre is also very safe.
Despite the fact that many different anaesthetic ap-
proaches have been reported for cardiac catheterisation, 
controversies between optimal conscious sedation, deep 
sedation, or general anaesthesia remain [4–13]. The advan-
tages of conscious sedation are not only related to reduced 
procedural time and costs, but also with early detection of 
signs and symptoms of complications, especially neurological 
(stroke/TIA) [4]. The use of sedation improves patients’ toler-
ance to TEE probe and reduces vomiting, coughing, and pain 
[14]. However, the sedation without endotracheal intubation 
carries a risk of unprotected airways [4].
In the study by Putra et al. [6] in 152 patients with ASD, 
the median device implantation procedure time under 
general anaesthesia was 115 min, whereas in our study the 
procedure duration was significantly shorter, with a mean 
procedure time 47 min. Also, in large study on ASO implan-
tation by Omeish et al. [15] the median procedural time was 
substantially longer (80 min). In the recent study by Desai et 
al. [4] on conscious sedation using dexmedetomidine without 
endotracheal intubation during ASO implantation the proce-
dure time was relatively short with a mean procedure duration 
time of 61 min and high procedural success rate (93%). The 
presented results suggest that the general anaesthesia prolongs 
the overall procedure duration and reduces patient turnover 
in the catheterisation laboratory.
Importantly, the success rate of ASO implantations in our 
centre was similar or even higher to that previously presented 
in large population studies, where general or deep sedation 
were applied (86.0% to 97.4%) [4–6, 10, 13, 15–17].
Figure 3. Comparison between patent foramen ovale (PFO) and atrial septal defect (ASD) morphology and total duration of 


























































































Conscious sedation for atrial sepal occluders implantation
411
Although ASO implantation is a relatively safe procedure, 
it can be associated with some major complications includ-
ing stroke, thrombosis, cardiac tamponade, bleeding, and 
minor complications like arrhythmias [9, 15]. Device-induced 
arrhythmias are usually transient and self-limiting. In our 
study, transient symptomatic bradycardia was encountered 
in one (0.8%) patient and treated successfully with atropine. 
Supraventricular arrhythmias were observed in four (3.3%) 
patients and in all cases they had terminated spontaneously 
before hospital discharge without the use of antiarrhythmic 
drugs or direct currant cardioversion. A similarly low inci-
dence of periprocedural supraventricular arrhythmia (atrial 
fibrillation) was observed by Węglarz et al. [13] in a group 
of 149 PFO implantations, and also all of them have gone 
without any treatment. 
Similarly to the study by Omeish et al. [15] of 3850 ASO 
device implantations, in our study no device-related deaths 
were observed and overall major complications were similar 
to the procedures performed under general anaesthesia. 
However, in our study access site bleeding with haematoma 
formation was the most common periprocedural complica-
tion (4.1%) and occurred more frequently as compared to the 
prevalence reported for procedures under general anaesthesia 
(0.2%). It may suggest that a full immobility and loss of motor 
reflexes under general anaesthesia can prevent local vascular 
complications, mainly related to the preserved patient mobil-
ity under conscious sedation and motor reaction to painful 
manoeuvres of the delivery sheath.
Proper patient counselling and patient cooperation during 
the procedure play a significant role. As we have previously 
reported in another study, appropriate preparation of patients 
to the TEE results in lower patient anxiety and discomfort, as 
well as improves comfort of the physician and reduces the 
dose of used sedatives [18]. Of note, none of the procedures 
performed by us were aborted due to lack of patient coop-
eration. It seems, that proper patient preparation to the pro-
cedure is crucial in achieving a high procedural success rate. 
Another important aspect was the length of hospital stay 
— the majority of patients were discharged the day after the 
implant procedure. Therefore, along with no need of anaes-
thesiologist support during ASO implantation, this approach 
seems attractive given its favourable cost-effectiveness.
Limitations of the study
The main limitation of our study is that it represents a ret-
rospective analysis of studies performed at a single centre. 
Moreover, we did not directly compare our conscious seda-
tion protocol with other anaesthetic approach. Therefore, 
further case-control studies comparing conscious and deep 
sedation or general anaesthesia are warranted to confirm 
the non-inferiority of the protocol presented by us. Another 
limitation of our study is the variety of implanted devices; 
however, it could also be a strength of our report indicating 
that the type of device and delivery system do not affect the 
safety and efficacy of conscious sedation.
CONCLUSIONS
Transcatheter closure of ASD or PFO under conscious seda-
tion with 2D/3D TEE guidance is feasible, safe, and efficient. 
The only concern is an increased prevalence of access-site 
complications, but they do not require specific treatment.
Conflict of interest: none declared
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